Postoperative survival effect of the number of examined lymph nodes on esophageal squamous cell carcinoma with pathological stage T1-3N0M0

被引:11
|
作者
Wu, Lei-Lei [1 ,2 ]
Zhong, Jiu-Di [3 ]
Zhu, Jia-Li [4 ]
Kang, Lu
Huang, Yang-Yu
Lin, Peng
Long, Hao
Zhang, Lan-Jun
Ma, Qi-Long [5 ,6 ]
Qiu, Li-Hong [6 ]
Ma, Guo-Wei [3 ,6 ]
机构
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China
[2] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Thorac Surg, Shanghai, Peoples R China
[3] Guangdong Esophageal Canc Inst, Guangzhou 510060, Peoples R China
[4] Tongji Univ, Sch Med, Shanghai, Peoples R China
[5] Jinling Hosp, Nanjing 210000, Peoples R China
[6] Sun Yat Sen Univ, Canc Ctr, Dept Thorac Surg, 651 Dongfengdong Rd, Guangzhou 510060, Peoples R China
关键词
Esophageal squamous cell carcinoma; Overall survival; Lymph node; SEER; CANCER; IMPACT;
D O I
10.1186/s12885-022-09207-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The postoperative survival effect of the number of examined lymph nodes on patients of R0-resected esophageal squamous cell carcinoma with pathological stage T1-3N0M0 is still unclear. Methods Patients diagnosed with pathological stage T1-3N0M0 esophageal squamous cell carcinoma from two cancer databases-our cancer center (N = 707), and Surveillance Epidemiology and End Results (N = 151). The primary clinical endpoint was overall survival. The X-tile software was used to determine the optimal cutoff value of the number of examined lymph nodes, and propensity score matching was conducted to reduce selection bias according to the results of X-tile software. The cohort of 151 patients from another database was used for validation. Results X-tile software provided an optimal cutoff value of 15 examined lymph nodes based on 707 patients, and 231 pairs of matched patients were included. In the unmatched cohort, Cox proportional hazard regression analysis revealed better overall survival in patients with more than 15 examined lymph nodes (adjusted hazard ratio, 0.566, 95% confidence interval, 0.445-0.720; p < 0.001) compared with patients with 15 or fewer examined lymph nodes. In the validation cohort, patients with more than 15 examined lymph nodes also had better overall survival (adjusted hazard ratio 0.665, p = 0.047). Conclusions The number of examined lymph nodes is a significant prognostic factor in esophageal squamous cell carcinoma patients with pathological stage T1-3N0M0, and more than 15 examined lymph nodes are associated with better overall survival. Although the difference is not significant, the survival curve of patients with examined lymph nodes > 30 is better than those with examined lymph nodes 15-30. We believe that the number of examined lymph nodes can provide prognostic guidance for those patients, and the more examined lymph nodes cause lesser occult lymph nodes metastasis and lead to a better prognosis. Therefore, surgeons and pathologists should try to examine as many lymph nodes as possible to evaluate the pathological stage precisely. However, we need more validation from other studies.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Postoperative survival effect of the number of examined lymph nodes on esophageal squamous cell carcinoma with pathological stage T1–3N0M0
    Lei-Lei Wu
    Jiu-Di Zhong
    Jia-Li Zhu
    Lu Kang
    Yang-Yu Huang
    Peng Lin
    Hao Long
    Lan-Jun Zhang
    Qi-Long Ma
    Li-Hong Qiu
    Guo-Wei Ma
    [J]. BMC Cancer, 22
  • [2] Establishment and validation of a prognostic risk classification for patients with stage T1-3N0M0 esophageal squamous cell carcinoma
    Huang, Yang-Yu
    Zheng, Yan
    Liang, Shen-Hua
    Wu, Lei-Lei
    Liu, Xuan
    Xing, Wen-Qun
    Ma, Guo-Wei
    [J]. JOURNAL OF CARDIOTHORACIC SURGERY, 2023, 18 (01)
  • [3] Establishment and validation of a prognostic risk classification for patients with stage T1-3N0M0 esophageal squamous cell carcinoma
    Yang-Yu Huang
    Yan Zheng
    Shen-Hua Liang
    Lei-Lei Wu
    Xuan Liu
    Wen-Qun Xing
    Guo-Wei Ma
    [J]. Journal of Cardiothoracic Surgery, 18
  • [4] Postoperative Chemotherapy for Thoracic Pathological T3N0M0 Esophageal Squamous Cell Carcinoma
    Audrey E. Kam
    Sam G. Pappas
    Ashiq Masood
    [J]. Annals of Surgical Oncology, 2020, 27 : 1314 - 1315
  • [5] Postoperative Chemotherapy for Thoracic Pathological T3N0M0 Esophageal Squamous Cell Carcinoma
    Kam, Audrey E.
    Pappas, Sam G.
    Masood, Ashiq
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (05) : 1314 - 1315
  • [6] Preoperative squamous cell carcinoma antigen and albumin serum levels predict the survival of patients with stage T1-3N0M0 esophageal squamous cell carcinoma: a retrospective observational study
    Lei-Lei Wu
    Xuan Liu
    Wei Huang
    Peng Lin
    Hao Long
    Lan-Jun Zhang
    Guo-Wei Ma
    [J]. Journal of Cardiothoracic Surgery, 15
  • [7] Preoperative squamous cell carcinoma antigen and albumin serum levels predict the survival of patients with stage T1-3N0M0 esophageal squamous cell carcinoma: a retrospective observational study
    Wu, Lei-Lei
    Liu, Xuan
    Huang, Wei
    Lin, Peng
    Long, Hao
    Zhang, Lan-Jun
    Ma, Guo-Wei
    [J]. JOURNAL OF CARDIOTHORACIC SURGERY, 2020, 15 (01)
  • [8] Relationship between lymph nodes examined and survival benefits with postoperative radiotherapy in oral cavity squamous cell carcinoma patients with stage T1-2N1M0
    Fan, Sufeng
    Jiang, Wenmei
    Fang, Zhongyi
    Li, Ruiyu
    Li, Yudong
    Chen, Yanfeng
    Zhang, Quan
    [J]. FRONTIERS IN SURGERY, 2022, 9
  • [9] Adjuvant therapy for pathological T3N0M0 esophageal squamous cell carcinoma
    Zhang, Xiaobin
    Yang, Yu
    Sun, Yifeng
    Ye, Bo
    Guo, Xufeng
    Mao, Teng
    Hua, Rong
    Li, Bin
    Gu, Haiyong
    Liu, Jun
    Li, Zhigang
    [J]. JOURNAL OF THORACIC DISEASE, 2019, 11 (06) : 2512 - 2522
  • [10] Survival benefit of perioperative chemotherapy for T1-3N0M0 stage esophageal cancer: a SEER database analysis
    Shao, Yue
    Chen, Dan
    Ye, Liu
    Wang, Xin-Mei
    Wu, Qing-Chen
    Zhang, Cheng
    [J]. JOURNAL OF THORACIC DISEASE, 2021, 13 (02) : 995 - 1004